Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Spire Wealth Management bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,949 shares of the company’s ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...

a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, in those without diabetes. These findings suggest that insurance plan type and structure may be a crucial intervention point ...